帕金森病的脑脊液与血液生物标志物
帕金森病诊断主要依赖临床症状,难以在早期阶段识别,而早期干预可能效果最佳。脑脊液和血液中反映帕金森病病理生理的生物标志物(如α-突触核蛋白、溶酶体酶、淀粉样蛋白和tau病理标志物、神经丝轻链)具有诊断和预后价值,多种脑脊液标志物联合已形成较准确的诊断和预后模型。脑脊液α-突触核蛋白聚集体在早期诊断中显示初步希望,血液标志物也在研究中。需在大型独立队列中进一步验证。
要点
- 脑脊液α-突触核蛋白聚集体在帕金森病早期诊断中显示初步希望。
- 多种脑脊液标志物联合可提高帕金森病诊断和预后准确性。
- 血液α-突触核蛋白和神经丝轻链有望成为无创诊断和监测工具。
核心结论
- 脑脊液和血液生物标志物有望提高帕金森病诊断和预后准确性。
- 脑脊液α-突触核蛋白聚集体在早期诊断中提供初步希望。
- 需在大型独立队列中进一步验证这些标志物。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 脑脊液中α-突触核蛋白种类、溶酶体酶、淀粉样蛋白和tau病理标志物、神经丝轻链等反映帕金森病病理生理。
- 多种脑脊液生物标志物联合已形成较准确的诊断和预后模型。
- 血液α-突触核蛋白种类和神经丝轻链正在研究作为无创工具。
临床怎么用
- 目前生物标志物尚需进一步验证,暂不能常规用于临床诊断。
- 脑脊液α-突触核蛋白聚集体检测可能有助于早期诊断。
- 血液标志物未来可能用于早期和鉴别诊断及疾病监测。
局限性
- 需在大型独立队列中进一步验证生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease-the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.
引用
- Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. 2019. PMID: 30981640. doi:10.1016/S1474-4422(19)30024-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。